Free Trial
NYSE:NKGN

NKGen Biotech (NKGN) Stock Price, News & Analysis

NKGen Biotech logo
$0.64 +0.07 (+13.25%)
(As of 12/20/2024 05:31 PM ET)

About NKGen Biotech Stock (NYSE:NKGN)

Key Stats

Today's Range
$0.56
$0.65
50-Day Range
$0.23
$0.70
52-Week Range
$0.20
$4.06
Volume
441,676 shs
Average Volume
1.68 million shs
Market Capitalization
$22.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Receive NKGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NKGen Biotech and its competitors with MarketBeat's FREE daily newsletter.

NKGN Stock News Headlines

NKGen Biotech Awards Stock Options to Executives
NKGen Biotech Secures Key Role in NKMax Deal
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
NKGen Biotech gets Nasdaq notice related to delayed quarterly report
See More Headlines

NKGN Stock Analysis - Frequently Asked Questions

NKGen Biotech's stock was trading at $2.75 on January 1st, 2024. Since then, NKGN stock has decreased by 76.7% and is now trading at $0.64.
View the best growth stocks for 2024 here
.

Top institutional shareholders of NKGen Biotech include Polar Asset Management Partners Inc. (3.34%) and Sequoia Financial Advisors LLC (0.27%). Insiders that own company stock include Paul Y Song and James A Graf.
View institutional ownership trends
.

Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that NKGen Biotech investors own include Meta Platforms (META), IonQ (IONQ), Eli Lilly and Company (LLY), NVIDIA (NVDA), Viking Therapeutics (VKTX), Adaptimmune Therapeutics (ADAP) and C3.ai (AI).

Company Calendar

Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-82,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
($2.68) per share

Miscellaneous

Free Float
8,964,000
Market Cap
$22.63 million
Optionable
Not Optionable
Beta
0.77
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:NKGN) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners